CD19 and diffuse large B-cell lymphoma: Three anti‐CD19 CAR T‐cell therapies are approved for use in R/R DLBCL, after two or more lines of systemic therapy: axicabtagene ciloleucel (axi‐cel) and tisagenlecleucel (tisa‐cel), approved in both Europe and the USA, and lisocabtagene maraleucel (liso‐cel), approved, at present, in the USA only.